Bone grafts grown from purified stem cells originating from fat could lead to a more efficient way to regenerate bone and end the painful operations needed to collect a patient’s own bone for grafting. The results could have significant impact on those suffering from severe bone injuries or disease.
In a study published in the June issue of STEM CELLS Translational Medicine, researchers were able to demonstrate the potential of a population of stem cells found in human fat to generate bone. They also identified a new factor to stimulate bone growth. The team was made up of scientists from the UCLA-Orthopaedic Hospital Department of Orthopaedic Surgery, the Orthopaedic Hospital Research Center, and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California-Los Angeles (UCLA).
Researchers have long recognized the potential of stem cells harvested from fat – which they call “adipose-derived stem cells” or ASCs – in bone engineering. For one thing, stem cells are more easily obtainable from fat than from bone marrow, which also contains stem cells, plus ASCs have already been used successfully to heal skeletal defects in animals. And while the current gold standard for collecting bone for grafting – “autograft bone,” which is that taken from the patient himself – has significant disadvantages, including the potential for complications arising from the extended operating time needed to collect it, harvesting stem cells from fat tissue is painless and poses minimal risk to the patient.
However, there are several obstacles to the use of ASCs, including the risk of infection and genetic instability when the cells are isolated and expanded in the lab. As an alternative, researchers have looked at the possibility of using stromal vascular fraction (SVF), which comes from lipoaspirate, the byproduct of a liposuction.
SVF contains a variety of cells, including smooth muscle cells, fibroblasts, adult stem cells and more. In addition, it contains blood cells from the capillaries supplying the fat cells. The SVF has the advantage of being rapidly available (there is no need for culture isolation), but it falls significantly short for bone growth, with studies showing it yields poor and unreliable bone formation.
“The main problem is this makeup of heterogeneous cell population, which can lead to unreliable bone formation,” Chia Soo, M.D., explained. She and Bruno Péault, Ph.D., and Kang Ting, D.M.D., D.Med.Sc., were the senior corresponding investigators on the study, funded by the California Institute of Regenerative Medicine (CIRM).
So the UCLA team decided to see what would happen if they purified the SVF cells to reduce their inherent heterogeneity and obtain a safer, more efficient stem cell-based therapeutic. Their goal was to isolate a population of stem cells known as perivascular stem cells (PSCs) that surround blood vessels. The team then took the bone grafts grown from the human PSCs and implanted them in mice to compare their bone-forming capacity with that of traditionally derived SVF.
The results exceeded expectation.
“The purified human PSCs formed significantly more bone in comparison to traditionally derived SVF by all parameters,” Aaron James, M.D., the study’s lead author, said. “This is true in terms of potency, identity and purity.”
The human PSCs also appear to be more predictable than SVFs.
“Moreover,” Dr. Péault added, “human PSCs are plentiful within adipose tissue so that even patients with minimal excess body fat can donate their own fat tissue for harvesting the cells. As an added bonus, the PSCs do not need to be cultured in the laboratory, which cuts down on the time and cost needed to produce them while also reducing the risk of immunogenicity, infection and genetic instability.”
At the same time, the researchers looked at growth factors for the human PSCs that would speed up the bone production. They focused on two candidates: BMP2 (bone morphogenetic protein2) and NELL-1 (Nel-like molecule-1), a potent bone-forming molecule first described by Dr. Ting. The mice whose implants were treated with NELL-1 showed a significant increase in the amount of therapeutically sound bone tissue produced, while those with BMP2-treated cells exhibited drawbacks including cyst-like bone formations or fat tissue.
“The marriage of a competent cell source for growing bones with an efficient growth factor is a logical union for skeletal tissue engineering,” Drs. Soo, Péault, and Ting concluded. “We believe our study demonstrates an optimal combination product for local bone formation in patients.”
“This research team has successfully addressed some of the hurdles with using fat tissue as a source of stem cells for bone formation,” said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “The possibility of using this method in the future to heal bone defects would be a breakthrough for patients.”
“Perivascular Stem Cells: A Prospectively Purified Mesenchymal Stem Cell Population for Bone Tissue Engineering” Aaron W. James et al.
Stem Cells Trans Med June 2012, doi: 10.5966/sctm.2012-0002